Vir Biotechnology, Inc. (VIR) — Fair Value Analysis

Base-case fair value (P50): $9.71 · Current price: $9.24 · Verdict: Fairly Valued

The Verdict on VIR

Based on our Monte Carlo simulations, VIR BIOTECHNOLOGY INC (VIR) is currently Fairly Valued. The analysis indicates a median fair value (P50) of $9.71, standing remarkably close to the company’s current trading price of $9.24. This implies a minimal +5.1% upside potential from its current level, suggesting the market largely reflects the fundamental outlook modeled across thousands of forward scenarios. Our simulations incorporate a broad range of operational and market variables, arriving at a converged valuation that sees little significant discrepancy between VIR's current price and its intrinsic worth.

How VIR stacks up against peers

VIR's operational and financial health is assessed as "average" relative to its sector peers. This average quality tier suggests that while VIR is not encountering significant distress, it also isn't demonstrating exceptional outperformance that would warrant a substantial premium or discount. This "average" standing, combined with a $9.24 that closely aligns with our $9.71 median fair value, underpins the "Fairly Valued" verdict. Companies with an average quality tier often see their market price converge with their intrinsic value, as fewer extreme scenarios are likely to push the valuation significantly higher or lower.

What this means for investors

For investors eyeing VIR, the "Fairly Valued" assessment, coupled with an average quality tier, suggests a balanced risk-reward profile at the current $9.24. While the +5.1% indicates limited immediate upside based on the median outcome of our Monte Carlo models, there are always various scenarios. A strong bull case could see VIR outperform, just as a downside scenario might emerge if operational challenges intensify. To understand the full distribution of potential outcomes, including the probabilities of different price targets, investors should leverage FairCurve. Sign up for a free FairCurve account to see the complete bear and bull distribution and track VIR's fair value as new fundamentals are released.